Clinical Trial Update: Phase I/II Study of Avelumab in Pediatric Cancer Participants [Phase 1]

View source ↗

Summary

A Phase I/II pediatric trial of avelumab in refractory or relapsed solid tumors and lymphoma was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Refractory or Relapsed Solid Tumors, Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-06-24